trial · primary record
Cabozantinib
Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 5000 |
| Primary completion | 2030-05-31 |
| Primary endpoint | Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
| Registry ID | NCT07620574 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:26.666Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07620574
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- CABOZANTINIB · approval
- Cabozantinib · compound